---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015736"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:11:03.048487+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Beam Q2 net loss $72M; BEAM-201 IND on clinical hold; cash $1.2B

## Summary
- Net loss $72.0M ($1.02/share) vs $76.3M ($1.23) prior year; R&D spend $74.6M (+64% YoY).
- BEAM-201 IND placed on clinical hold by FDA July 29; awaiting official letter.
- Patient enrollment in BEACON Phase 1/2 for BEAM-101 on track for 2H 2022.
- John Lo, Ph.D., appointed Chief Commercial Officer; Amended Verve deal adds CV target.
- Cash, cash equivalents and marketable securities $1.2B as of June 30, 2022.

## SEC filing metadata
- accession: 0000950170-22-015736
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017022015736/0000950170-22-015736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017022015736/beam-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015736
- JSON: https://secwatch.observer/filing/0000950170-22-015736.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.